Today: 21 May 2026
Browse Category

LSE:IREN 12 January 2026 - 6 May 2026

IREN Stock Jumps After $625 Million Mirantis Deal Deepens AI Cloud Push

IREN Stock Jumps After $625 Million Mirantis Deal Deepens AI Cloud Push

IREN Ltd will acquire Mirantis Inc in an all-share deal worth about $625 million, expanding into cloud software and AI infrastructure. IREN shares rose 10.6% to $54.74 after the announcement. Mirantis will operate as a standalone subsidiary, supporting IREN’s AI cloud deployments. The deal is subject to regulatory approval and customary closing conditions.
6 May 2026
····
IREN stock jumps after Bernstein tags it a top AI pick as bitcoin holds near $91,000

IREN stock jumps after Bernstein tags it a top AI pick as bitcoin holds near $91,000

IREN shares jumped 9.3% Monday, outpacing other crypto miners as bitcoin hovered near $91,200 ahead of Tuesday’s U.S. CPI data. About 53 million IREN shares changed hands, with the stock trading between $45.85 and $51.62. Investors are watching IREN’s AI expansion and a $9.7 billion Microsoft deal, as well as upcoming earnings projected for February. Rate cut expectations have shifted after recent U.S. data.
13 January 2026
··
IREN stock jumps as bitcoin firms up; what traders are watching next

IREN stock jumps as bitcoin firms up; what traders are watching next

IREN shares surged 7.3% to $49.38 in early New York trading Monday, with volume topping 20.5 million. Bitcoin hovered near $91,674, while other crypto miners posted mixed-to-higher moves. IREN’s gains follow its $9.7 billion Microsoft contract and updated AI revenue targets. Traders await Tuesday’s U.S. CPI data for further market direction.
12 January 2026
······

Stock Market Today

  • Analyst Revises MongoDB Outlook After Sharp 22% Stock Decline
    May 20, 2026, 11:08 PM EDT. An analyst shifted to a more favorable view on MongoDB (NASDAQ: MDB) after its stock plunged 22% on March 3, 2026, despite better-than-expected fiscal Q4 results. The company reported $695 million revenue, up 27% year-over-year, with Atlas cloud revenue hitting a $2 billion annual run rate. However, cautious fiscal 2027 guidance projecting 16-18% revenue growth-below expectations-triggered the drop and a Baird price target cut from $500 to $260. The analyst now highlights MongoDB's strong business fundamentals, including a 23% adjusted operating margin and leading position in document databases, which support cloud-native applications. The initial high valuation and AI premium correction have shifted risk perceptions, revealing a steadier business amid recent market volatility.

Latest articles

SPAC ETF Up as SpaceX Heads for SPCX Ticker

SPAC ETF Up as SpaceX Heads for SPCX Ticker

21 May 2026
The SPAC and New Issue ETF, now trading as SPCK, closed up 0.64% at $22.09 on Wednesday after SpaceX filed for a $75 billion IPO under the fund’s old ticker. The fund reported $7.14 million in net assets and 41 holdings as of May 19. New listings included a $75 million IPO from Research Alliance III and filings from FutureCorp Space Acquisition 1 and JAB Acquisition I. The SEC proposed easing share issuance rules for public companies.
EnerSys Stock Flips After Earnings as Guidance Tops Trader Hopes

EnerSys Stock Flips After Earnings as Guidance Tops Trader Hopes

21 May 2026
EnerSys shares rose in after-hours trading after the company posted fourth-quarter adjusted earnings of $3.19 per share on $988 million in revenue, both above analyst estimates. The stock closed regular hours down 1.3% at $214.56, then quoted up 5.8% to $227. First-quarter profit guidance also topped forecasts. Management cited strong data center and defense demand, but noted continued weakness in motive-power and transportation.
Silexion Soars After Cancer Study, Liquidity and Nasdaq Issues Linger for SLXN

Silexion Soars After Cancer Study, Liquidity and Nasdaq Issues Linger for SLXN

21 May 2026
Silexion Therapeutics shares surged 97% to $0.5298 on Wednesday with over 325 million shares traded, then fell 9.5% after hours. The move followed news that Israel approved a Phase 2/3 trial of its lead pancreatic cancer drug, SIL204. Silexion reported a Q1 net loss of $2.7 million and $2.4 million in cash. The company plans a 1-for-10 reverse share split by early June.
Go toTop